3 Bioeconomy Stocks That Have a Killer Advantage

While the words biotech and biopharma are often used interchangeably, they aren't the same thing -- not even close, in fact. Biotechnology is using biology as technology -- and that extends far beyond the realm of healthcare and therapeutics. We live in a world with biotech crops and plants, genetically engineered microbes that churn out industrially relevant chemicals, biotech animals, living environmental sensors, and much more. Collectively, these products' contributions to national GDP comprise the bioeconomy.

Individual investors are still in the early stages of being able to reap the potential rewards of biotech (there's vastly more excitement with private start-ups at the moment), but that doesn't mean there aren't opportunities to build wealth by owning great companies for the long term. Investors should consider the bioeconomy stocks of Codexis (NASDAQ: CDXS), Green Plains (NASDAQ: GPRE), and Repligen (NASDAQ: RGEN) for their killer advantages in their respective subsectors.

Image source: Getty Images.

Source: Fool.com